Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02465632 · ClinicalTrials.gov registry record · Phase 3

To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.

A Phase 3 study, sponsored by Glenmark Pharmaceuticals Ltd. India.

Completed
Registry status
Phase 3
Development phase
1,100
Enrollment target

NCT02465632: Completed Phase 3 study, sponsored by Glenmark Pharmaceuticals Ltd. India.

NCT02465632 is a Phase 3 study that has completed, run by Glenmark Pharmaceuticals Ltd. India. The registered enrollment target is 1,100 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02465632, a Phase 3 study, has completed, sponsored by Glenmark Pharmaceuticals Ltd. India.

COMPLETED
Registry status
Phase 3
Development phase
1,100 participants
Enrollment target

Study Summary

This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1%/ Benzoyl peroxide 5% topical gel (Glenmark Generics, Ltd), and the marketed product BenzaClin® Topical Gel, Clindamycin 1%/ Benzoyl peroxide 5% (Valeant Pharmaceuticals, US) in the treatment of acne vulgaris.

Primary Outcome

The number of inflammatory lesions (papules and pustules) count between the treatment groups were estimated.

Interventions

  • DRUG Placebo
  • DRUG Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel
  • DRUG BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%

Trial Details

FieldValue
Enrollment Target 1,100 participants
Start Date 2015-04
Est. Completion 2015-12
Phase Phase 3

What the finished NCT02465632 record still lists

NCT02465632 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% higher).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT02465632 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02465632 about?

NCT02465632 is a clinical study titled "To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.". This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1%/ Benzoyl peroxide 5% topical gel (Glenmark Generics, Ltd), and the marketed product BenzaClin® Topical Gel, Clindamycin 1%/ Benzoyl perox...

What is the current status of trial NCT02465632?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2015-04. Estimated completion is 2015-12.

What interventions are being tested in trial NCT02465632?

The interventions under investigation include: Placebo (DRUG), Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (DRUG), BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% (DRUG).

Who is sponsoring clinical trial NCT02465632?

This trial is sponsored by Glenmark Pharmaceuticals Ltd. India, which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02465632's enrollment target sits among peer trials

1,100 252nd of 2000 higher than 1,736 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00710112 · 1,100 participants

    Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants

  • NCT02688517 · 1,100 participants

    Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

  • NCT04743765 · 1,100 participants · NA

    HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

  • NCT05638581 · 1,100 participants · Phase 3

    Trauma Resuscitation With Low-Titer Group O Whole Blood or Products

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02465632, the US trial registry maintained by the National Library of Medicine. NCT02465632 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.